FilingSEC EDGAR8-K
bioAffinity Technologies Advances CyPath® Lung Distribution with AvMEDICAL
· SEC accepted
StageBusiness Expansion
Filing content
bioAffinity Technologies debuted its CyPath® Lung test at the NAVREF Annual Conference under its federal distribution agreement with AvMEDICAL to expand access to the veteran healthcare market.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…